Evaluation of miltefosine against Leishmania major (MRHO/IR/75/ER): In vitro and in vivo studies

Acta Medica Iranica

Volumn 46, Issue 3, 2008, Pages 191-196

  Esmaeili, J ^a   Mohebali, M ^a   Edrissian, G H ^a   Rezayat, S M ^b   Ghazi Khansari, M ^b   Charehdar, S ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Leishmania major; Miltefosine; Treatment

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MAJOR; MALE; MOUSE; NONHUMAN; SKIN LEISHMANIASIS; STATISTICAL ANALYSIS;

EID: 45849146154     PISSN: 00446025     EISSN: 00446025     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Scarisbrick JJ, Chiodini PL, Watson J, Moody A, Armstrong M, Lockwood D, Bryceson A, Vega-López F. Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med Infect Dis. 2006 Jan; 4(1):14-21.
2. Mohebali M, Javadian E, Yaghoobi-Ershadi MR, Akhavan AA, Hajjaran H, Abaei MR. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J. 2004 Jul-Sep; 10(4-5):591-599.
3. Momeni AZ, Aminjavaheri M. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur J Dermatol. 2003 Jan-Feb; 13(1):40-43.
4. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006 May; 3(5):e162.
5. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis. 2001 Oct 1;33(7):E57-61.
6. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother. 1992 Aug; 36(8):1630-1634.
7. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol. 1987 Aug 15;36(16):2633-2636.
8. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998 Dec 5;352(9143):1821-1823.
9. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med. 1999 Dec 9;341(24):1795-1800.
10. Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother. 2005 Jul; 6(8):1381-1388.
11. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop. 2007 Jul; 103(1):33-40.
12. Alimohammadian MH, Darabi H, Kariminia A, Rivier D, Bovay P, Mauel J, Ajdary S, Kharazmi A. Adjuvant Effect of Leishmania major promastigotes onthe immune response of mice to ovalbumin. Iranian Biomed J. 2002; 6: 123-128.
13. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis. 1999 Aug;180(2):564-567.
14. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004 May 1;38(9):1266-1272.
15. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997 Apr; 24(4):684-703.
16. Unger C, Fleer E, Damenz W, Hilgard P, Nagel G, Eibl H. Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat. 1991 Jan-Feb; 3(1):71-78.
17. Breiser A, Kim DJ, Fleer EA, Damenz W, Drube A, Berger M, Nagel GA, Eibl H, Unger C. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids. 1987 Nov; 22(11):925-926.
18. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990 Aug; 89(2):147-155.
19. Saenz RE, Paz HM, Johnson CM, Marr JJ, Nelson DJ, Pattishall KH, Rogers MD. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Infect Dis. 1989 Jul;160(1):153-158.